cyrilzakka/clinical-trials huggingface dataset:
Trial of Art Therapy During Cognitive Processing Therapy for PTSD

This is a randomized, controlled trial of adjunctive art therapy during cognitive processing therapy for PTSD.

The objective of this study is to examine the effects of art therapy with combat veterans who have PTSD and to measure if it reduces symptoms more than verbal Cognitive Processing Therapy (CPT) alone. This study will incorporate art processes and materials into an already established protocol of CPT in order to create a sense of safety for veterans in beginning therapy, and access the nonverbal parts of the trauma in order to process it. Art-making will be used to help veterans address trauma and integrate who they were before the trauma with who they are currently. It will assist in addressing the grief and loss caused by combat, and will be used as veterans begin building a worldview and self-concept that are not filled with trauma and war. It is hypothesized that the veterans who receive art therapy with CPT will show a significantly greater decrease in PTSD symptoms than those who receive only CPT.

Eligibility Criteria:
Inclusion Criteria:

* PCL-M initial score \>= 50;
* Both genders,
* All ethnicities,
* Veterans in treatment for PTSD,

Exclusion Criteria:

* No active substance use disorder,
* No active suicidal or homicidal ideation,
* No psychosis
The Incidence and Factors of Brown Adipose Tissue in Chinese

Previous studies have shown active brown adipose tissue (BAT) is present in adults and may play important roles in regulating energy homeostasis. However, the majorities of these studies were done in patients undergoing scanning for cancer surveillance, and may not reflect BAT behavior in healthy individuals. In addition, little is known about the ethnic variation in BAT activity, particularly in Chinese adults. Due to the large amount in our cohort, we are able to look at the difference between subjects for cancer surveillance (CS) and subjects for medical check-up (MC), and to clarify the impact of clinical and lifestyle parameters.

We will study scanning database including data from July 2006 to June 2010 in Shanghai. BAT activity will be measured via 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Age, imaging date, sex, and outdoor temperature will be collected for all patients. To evaluate the effects of multiple metabolic parameters on BAT activity, we will collect height, body weight, fasting plasma glucose (FPG), medical history, diagnosis, smoking, alcohol consumption, exercise, liver triglyceride content, and thyroid metabolic activity for all patients with detectable BAT and their negative controls, consisting of two patients who underwent PET/CT scans at the same day but without detectable BAT.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with detectable brown adipose tissue
* Negative controls, consisting of two subjects who underwent PET/CT scans at the same day but without detectable BAT

Exclusion Criteria:

* Younger than 18 years
Tel Aviv Sourasky MC Home Monitoring Clinic Registry

The purpose of the registry is to assess workload of a Home Monitoring based follow up for Biotronik implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRTD) patients.

EP unit device clinic is a very busy clinic. Every 6 month the patients arrive for device follow up where the device parameters, patient condition and arrhythmic events are being reviewed, and reprogramming of the device (if needed) is done. Average net time of patient's stay in the clinic is between 30-45 minutes.

Patients implanted with the Lumax device family allows for a better automated follow up procedure via remote management (Home Monitoring).

Eligibility Criteria:
Inclusion Criteria:

* Approved indication for ICD or CRTD.
* Implanted with or replaced with a Biotronik Lumax device.
* Patient is willing and able to sign consent form.
* Willing and able to attend clinic visits and follow up schedule.
* Transmission of more than 80% at 3-month FU.
* Patient older than 18 years.

Exclusion Criteria:

* No indication for ICD or CRTD implant.
* Life expectancy shorter than 12 months.
* Pregnancy.
* Participation in other clinical studies.
Comparison of Adverse Drug Reactions Associated for Oxycodone and Morphine in Postoperative Pain After Abdominal Hysterectomy

The objective of this study is compare adverse reactions associated with oxycodone and morphine for the treatment of postoperative pain after abdominal hysterectomy

A randomized single-blind study, was performed to compare the adverse reactions associated with oxycodone and morphine in patients undergoing abdominal hysterectomy.

process:

1. A clinical history of patients candidates to participate in the study will be developed.
2. If you meet the selection criteria will be held the invitation to participate in the study, reading the letter under information

Patients who agree to participate in the study will be managet during the surgical procedure:

15 mg mixed blockade with bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg intravenously during surgery metamizol 3) After the surgical procedure (immediate postoperative)

• the patient to group A or B (randomization) is assigned, masking infusions and allocation will be conducted by an outside person who will test an additional record the names of the patients and the drug administered.

A bolus of oxycodone or morphine 10% calculated dose for intravenous infusion 0.075mg intravenous palonosetron prophylaxis of emesis Detection and assessment of severity of adverse drug reactions will be conducted by an interview that will be at 0,1,2,6,12 and 24 hours after the onset of analgesia. Instrument designed for the detection of RAM will be used and classify its severity according to common terminology criteria for adverse events (CTCAE). Futhermore, measuring systemic blood pressure, heart rate, oxygen saturation will be performed through the use of Nihon Kohden monitor (model BSN-2301K). Pain assessment will be made by the numerical scale (NRS). The researcher responsible for the detection and assessment of adverse reactions to opioids and others determinations, remain mowed.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for abdominal hysterectomy
* Signing for informed consent

Exclusion Criteria:

* Patients used with MAO inhibitor drugs (\<14 days before surgery)
* History of substance abuse
* Hypersensitivity to opioids and others drugs of multimodal analgesia (metamizol and lidocaine)
* Pretreatment of any opioid (\<7/2 lives of the drug in question)
* Chronic pain of any etiology (\> 6 months)
* Diagnosis of bowel obstruction
* Renal or hepatic insufficiency
* Asthma, chronic obstructive pulmonary disease (COPD), and/ or hypothyroidism.
* Patients requiring general anesthesia for surgical complications
Secondary Prevention After Coronary Bypass Surgery

Despite immediate symptomatic success after coronary bypass surgery in patients with coronary artery disease, this effect is not sustained over time since risk factors for coronary artery disease are still in place. The role of secondary prevention becomes increasingly important as it can potentially decrease or eliminate the need for another intervention in these high risk subjects. This project seeks to evaluate the effect of emphasizing secondary prevention measures in this patient population during hospital admission and through six months post-discharge.


Eligibility Criteria:
Inclusion Criteria:

* Subjects over the age of 18 who will undergo a CABG procedure and who have given written informed consent

Exclusion Criteria:

* Subjects under the age of 18 or who are unable to give consent on their own behald
Extension of the MIME Robotic System for Stroke Rehabilitation

The goal of this project is to develop and test a new robotic system to accommodate practice of tasks requiring reach, grasp and release of objects. Our previous work has shown that the MIME robot is safe and effective for improving reach in stroke subjects. But adequate control of hand movements is critical to a functional upper limb, and is often resistant to conventional therapeutic interventions. Many stroke survivors have residual ability to flex the fingers, but extension is often limited and impeded by increased passive stiffness in flexors, abnormal levels of increased tone in flexors and weakness in extensors. In a recent study, 38% of stroke survivors reported that impaired hand function was the most disabling motor impairment they faced.

Research Design:

We hypothesize that: 1) Gains in proximal arm function (shoulder, elbow) immediately after robotic training will be greater than after dose-matched conventional therapy; 2) Unlike in previous studies, gains in hand function immediately after robotic training will be greater than after dose-matched conventional therapy.

Methodology:

In the first year of the study, we will develop a robotic system with the ability to assist hand movement. Since many stroke survivors in the subacute and chronic recovery stages have residual ability to flex the fingers but severely limited finger extension, we will build a hand exoskeleton that can apply precise extension forces to the digits of the hand. This exoskeleton will be integrated with the ARMin III arm exoskeleton so that tasks such as arm reach, grasp of an object and release of the object can be trained. In the last 2 years of the project, we will perform a pilot clinical trial comparing this new training paradigm to dose-matched conventional therapy in chronic stroke survivors. Outcome measures will be taken before training and immediately after training.

Eligibility Criteria:
Inclusion Criteria:

* An ischemic or hemorrhagic stroke more than 6 months prior to entry into the study;
* trace ability to move the wrist and fingers in extension;
* voluntary shoulder elevation to approximately 45 deg;
* be between the ages of 21 and 90.

Exclusion Criteria:

* Have cognitive deficits that could negatively affect their ability to complete protocols as evidenced by a score of 24 or less on the Folstein Mini - Mental State Examination (Bleeker, 1988);
* have excessive pain in any joint of the affected extremity that could limit ability to cooperate with the protocols;
* have an upper extremity injury or conditions prior to stroke that could limit participation;
* have severe hemispatial neglect.
* have a full score of 24 on the distal section of the Fugl-Myer test (FM) (Fugl-Meyer 1975); and
* have severe sensory loss.
A Study of LY3457263 in Obese Participants

The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Participants who are overtly healthy as determined by medical evaluation
* Have a stable body weight and body mass index (BMI) within the range 27.0 to 45.0 kilograms per meter squared (kg/m²)
* Male or female participants not of childbearing potential

Exclusion Criteria:

* Have a mean sitting systolic blood pressure (BP) higher than 160 millimeters of mercury (mmHg) or a mean sitting diastolic BP higher than 90 mmHg from 3 measurements
* Have an abnormal 12-lead electrocardiogram (ECG) at screening
* Have type 1 or type 2 diabetes mellitus
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pilot screening program to promote early detection. Participants who have abnormal results will receive patient navigation for further diagnostics and testing.

Multiple Myeloma (MM) is a hematologic cancer of antibody-producing plasma cells. Multiple Myeloma is always preceded by a pre-malignant condition called monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma. Despite multiple therapeutic advances, there remains no cure for multiple myeloma. The disease is treated and monitored throughout a person's lifetime. This is why screening for early detection of this disease is important; however, MGUS and smoldering multiple myeloma are only diagnosed when they are found incidentally on labs during tests for unrelated symptoms. There are no current universal screening guidelines for MM. Among those who may benefit from MM screenings include African American/Black individuals, as it is twice as common in this population compared to Caucasian/White individuals. This study aims to develop a screening program specifically targeting underserved African American/Black individuals. This project will expand the existing Taussig Community Outreach screening program to include screening for multiple myeloma.

Eligibility Criteria:
Inclusion Criteria:

* Participant self-identifying as, or perceived as, Black and/or African-American
* 50 years of age or older

Exclusion Criteria:

* Participants who do not self-identify as Black and/or African American
* Under the age of 50 years
Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption

Objectives. To evaluate the effectiveness and cost effectiveness of clinical practice guide based intervention with two face-to-face visits and e-mail tracking compared to brief advice to obtain continued smoking abstinence at 6 and 12 months after intervention.

Methodology. simple randomized controlled multicentric trial. All smokers (N=1064) aged 18 or older that attend by any reason to the primary care center and that have an e-mail account and they checked it at least once a week will be invited to participate. The enrolled participants will be randomly divided into control (N=532) and intervention group (N=532). An intensive intervention, based on the recommendations of the clinical practice guides, that will include six contacts (2 face-to-face and 4 by e-mail) will be applied to the intervention group. Control group will receive brief advice.

The main dependent variable will be continued abstinence of tobacco consumption at six and twelve months after the beginning of the intervention which will be validated by and a carbon monoxide breathe analysis measured by a cooximeter in standard conditions. Secondary variables will include: stage change on the quitting smoking process and evaluation of the effectiveness on the reduction of the number of smoked cigarettes at six and twelve months after intervention. A descriptive analysis of all variables will be done. A multivariate analysis will be undertaken to assess differences among intervention and control group; logistic regression for dichotomic variables and lineal regression for continuous variables.

In preliminary phase is planned to carry out 2 descriptive sub-studies: a qualitative one, which will reflect the views of patients and physicians regarding the use of email as a smoking cessation intervention, and another smoker's profile in relation to Information and Communication Technologies (ICT), which collects information on the actual use of them in smokers. The result of both will help to release data on the type of participants who would be involved in the clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* Smokers over 18 years old with an e-mail account who use frequently. (Smoker is an individual who smokes any amount of tobacco, whatever this amount it is.
* E-mail regular user is the one who uses it as a way of communication at least once per week)

Exclusion Criteria:

* Not regular e-mail users,
* patients who have diseases that advise not to stop smoking:
* Terminal diseases
* Serious psychiatric disorders
* Active addiction to other psychoactive drugs
* Patients in smoking cessation process
* whatever the cause that does not allow to understand goals and methodology of the study
The Use Of Growing Rods In Pediatric Long Bones Deformity Correction

The objective of this study is to evaluate the value of growing rods for the correction of long bone deformities in pediatric cases attending Sohag University Hospital and follow up aiming at determining benefits and obstacles to this technique

* The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.
* Procedure will be done under anaesethia
* Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod

Eligibility Criteria:
Inclusion Criteria:

* cases of osteogenesis imperfecta
* metabolic bone deformities
* cases of hemimelia
* traumatic bone deformities
* complex or simple deformities

Exclusion Criteria:

* adult deformities
* short bone deformities
* very narrow medulla
* osteopetrosis
Prevalence of Oral Lesions in COVID-19 Patients

Recently, a new coronavirus disease 2019 (COVID-19) has appeared and caused an unprecedented pandemic which is considered as an urgent threat to health authorities worldwide. Several symptoms are observed which are fever, cough, shortness of breath, headache, runny nose, muscle pain, fatigue, arthralgia, sputum production, conjunctivitis, diarrhea. Susceptibility, genetics, systematic diseases, population, gender, and age are crucial considerations for the onset and progression of the viral infection. The patients suffering from asthma or pulmonary deficiency are at high risk of mortality. A metallopeptidase, angiotensin-converting enzyme 2 (ACE2) is considered as the functional receptor for SARS-CoV-2 and it was isolated from a COVID-19 patient. ACE2 was recognized in type I and type II alveolar epithelial cells in both nasal and oral mucosa, in the nasopharynx, in the smooth muscle cells and endothelium of vessels in the stomach and the skin, distinctly in the basal cell layer of the epidermis extending to the basal cell layer of hair follicles, and in the basal layer of the non-keratinizing squamous epithelium. In order to study the possible routes of SARS-CoV-2 infection on the oral mucosa, we investigated whether oral lesions mainly affect the tongue mucosa due to higher ACE2-expressing cell composition and proportion more than that in other oral tissues. Moreover, appearance of oral lesions were as a result of SARS-CoV-2 infection or as a side effect of certain drugs for COVID-19 treatment was evaluated.


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years.
* laboratory-confirmed COVID-19 infection (reverse transcription-polymerase chain reaction, RT-PCR).

Exclusion Criteria:

* patients without a laboratory-confirmed diagnosis of COVID-19 infection.
* patients with olfactory or gustatory dysfunctions before the epidemic.
* patients with some malignant neoplasms.
* patients with neurodegenerative disorders.
Navigation on Head and Neck Radiotherapy

The aim of this experimental study is to evaluate the effect of nurse navigation in the management of symptoms associated with head and neck radiotherapy. All head and neck cancer patients who meet the study criteria of the Radiation Oncology Clinic of Selçuk University Medical Faculty Hospital will be included in the study. According to the previously prepared randomization list, the study group consisted of a total of 88 people, 41 in the experimental group and 47 in the control group. While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group.Quality of life and toxicity criteria will be applied to all patients as measurement tools.

The navigation program will be started on the day patients start their treatment. Before starting radiotherapy on the first day of radiotherapy, patients will be given a visual education guide about the radiotherapy treatment and the expected side effects. Afterwards, there will be a weekly follow-up with phone reminders. Inclusion criteria in the study; Being over the age of 18, the patient whose treatment and follow-up will continue for 7 weeks, patient diagnosed with head and neck cancer, scheduled to receive radiotherapy, patients who verbally and in writing approved to participate in the study after the explanation about the research. Exclusion criteria from the study; Metastasis development in the patient, refusing to participate in the research after the explanation about the research, the patient himself / herself wants to leave the study.For all patients included in the study, informed consent forms will be obtained just before starting treatment, and the patient identification form, CTCAE v5.0 toxicity criteria and EORTC QLQ-H \& N35 scales will be applied. Quality of life measurements will be repeated at the end and middle of the treatment. In addition, weight measurements and laboratory follow-up of the patients will be done at the beginning and at the end of the study. NCSS (Number Cruncher Statistical System) 2007 program will be used for statistical analysis. Descriptive statistics, parametric and non-parametric tests will be used to evaluate data.

Eligibility Criteria:
Inclusion Criteria:

* Being literate
* Being over the age of 18
* The patient whose treatment and follow-up will continue for 7 weeks
* Patient diagnosed with head and neck cancer, scheduled to receive radiotherapy
* Patients who verbally and in writing approved to participate in the study after the explanation about the research

Exclusion Criteria:

* Metastasis development in the patient
* Refusing to participate in the research after the explanation about the research.
* The patient himself / herself wants to leave the study.
* Treatment interruption for more than 2 days due to deterioration of the general condition of the patient
* Taking the patient into intensive care
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

This is a prospective, multi-center, randomized, single-blind clinical trial conducted in the United States (US). The objective of the study is to evaluate the safety and efficacy of the HF Pressure Measurement System in reducing heart failure (HF) related hospitalizations in a subset of subjects suffering from HF.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of HF ≥ 3 months, with either preserved or reduced LVEF
2. Diagnosis of NYHA Class III HF (historical assessment documented at screening visit)
3. Subjects with reduced LVEF must be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be stable for one month prior to study entry.
4. At least 1 HF hospitalization within 12 months of Screening Visit
5. Subjects with pulmonary artery branch diameter sized between 7mm and 15mm (implanted vessel)

Exclusion Criteria:

1. Subjects with history of recurrent (\> 1) pulmonary embolism or deep vein thrombosis
2. Subjects, in the Investigator's opinion, unable to tolerate a right heart catheterization
3. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of Screening Visit
4. Subjects with Cardiac Resynchronization Device (CRT) implanted ≤ 3 months prior to enrollment
5. Subjects with a Glomerular Filtration Rate (GFR) \<25 ml/min who are non-responsive to diuretic therapy or who are on chronic renal dialysis
6. Subjects likely to undergo heart transplantation within 6 months of Screening Visit
7. Subjects with congenital heart disease or mechanical right heart valve(s)
8. Subjects with known coagulation disorders
9. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel